Neuphoria Therapeutics Inc. has announced that it received a deficiency notification from Nasdaq, indicating non-compliance with Nasdaq Listing Rule 5620(a). The company failed to hold an annual meeting of stockholders within 12 months of the fiscal year ending June 30, 2024. Neuphoria has until September 1, 2025, to submit a compliance plan, and if accepted, Nasdaq may grant an extension until December 29, 2025. The company plans to hold its 2025 annual meeting in November to address the issue and maintain its listing status. The notice currently has no immediate impact on its Nasdaq listing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.